Stem cell transplant effective in MSStem cell transplant treatment can reduce disability for people with multiple sclerosis (MS), the Times and the Daily Telegraph reported on Monday.
Oxford Nanopore value reaches £1.5 billion as it taps Asia-Pacific fundingOxford Nanopore has pulled in £100 million from investors in the Asia-Pacific region, as it completes a funding round that values the fast-growing UK biotech at £1.5 billion.
NHS warned of £9 billion hit for Alzheimer's breakthroughsThe FT on Wednesday said that the UK health system is unprepared for potential breakthroughs in the treatment of Alzheimer’s and other forms of dementia that could cost the National Health Service up to £9 billion a year, according to new analysis by researchers at the London School of Economics.
AbbVie suffers $25 billion hit from lung cancer disappointmentThe FT on Friday reports that investors wiped more than $25 billion off AbbVie's market value on Thursday after the group abandoned plans to seek rapid approval in the U.S. for a closely-watched experimental lung cancer drug following mid-stage results. (APMHE 57422)
GSK pulls out of race for Pfizer's consumer armGlaxoSmithKline's withdrawal from the bidding process for Pfizer's expected $20 billion sale of its consumer healthcare arm was covered online on Friday by the FT and The Times. (APMHE 57438)
TRY APM HEALTH EUROPE AND GET ACCESS TO THE FULL CONTENT
Interviews with KOLs/senior executives amongst the Regulators, Payers, Health, Medical & Pharmaceutical organisations
Events coverage with a unique focus on Market Access & sustainability of healthcare systems
6 European bureaus : Berlin, Brussels, London, Madrid, Milan & Paris
Ask for a Free trial and get access to our last stories
- Health Care
- Market Access
- HTA – policies & practices
- European medicine regulations
- Drug safety issues
- Pricing & Reimbursement
- International medicines agencies
If you are a Payer, Pharmaceutical or Consulting professional our premium data will keep you informed on the regulatory, pricing, market access and cost-effectiveness issues that impact all stakeholders.
an initial 10 day temporary access of APM Health Europe.